Comments of the Auditing Standards Committee of the Auditing Section of the American Accounting Association on the SEC’s Semiannual Reporting Proposal
Current Issues in Auditing · 01.07.2026 · 1-9
DOI: 10.2308/ciia-2026-025 ↗Kurz gefasst
Fachartikel in der Zeitschrift Current Issues in Auditing, online erschienen am 22.07.2026. Verfasst von Dereck Barr-Pulliam und 5 weiteren Autor:innen.
Abstract (Originalsprache)
On May 5, 2026, the Securities and Exchange Commission (SEC) issued a request for comment on its proposal to allow its registrants the option to reduce the frequency of interim reporting from quarterly to semiannually (SEC 2026). This comment letter summarizes the views of the participating members of the Auditing Standards Committee of the Auditing Section of the American Accounting Association. We raise concerns about the proposal to provide issuers with the option to reduce the frequency of financial reporting from quarterly to semiannually.
Zitieren
APA
Barr-Pulliam, D., Dennis, S. A., Holt, T. P., Keyser, J. D., McAllister, M., & Zimmerman, A. B. (2026). Comments of the Auditing Standards Committee of the Auditing Section of the American Accounting Association on the SEC’s Semiannual Reporting Proposal. Current Issues in Auditing, 1-9. https://doi.org/10.2308/ciia-2026-025
Vancouver
Barr-Pulliam D, Dennis SA, Holt TP, Keyser JD, McAllister M, Zimmerman AB. Comments of the Auditing Standards Committee of the Auditing Section of the American Accounting Association on the SEC’s Semiannual Reporting Proposal. Current Issues in Auditing. 2026:1-9. doi:10.2308/ciia-2026-025
BibTeX
@article{BarrPulliam2026,
author = {Barr-Pulliam, Dereck and Dennis, Sean A. and Holt, Travis P. and Keyser, John D. and McAllister, Michelle and Zimmerman, Aleksandra B.},
title = {Comments of the Auditing Standards Committee of the Auditing Section of the American Accounting Association on the SEC’s Semiannual Reporting Proposal},
journal = {Current Issues in Auditing},
year = {2026},
pages = {1--9},
doi = {10.2308/ciia-2026-025}
}
EUVIMED